List view / Grid view
6 October 2015 | By Victoria White
Cardiff University immunologists have described how an immune system protein - interleukin-27 - regulates the inflammatory process in lymphoid-rich rheumatoid arthritis...
5 October 2015 | By Victoria White
The Nobel Prize for Physiology or Medicine has been split this year to recognise work that has revolutionised the treatment of some parasitic diseases...
2 October 2015 | By Victoria White
The technique allows drugs to last longer in the body and attack both primary cancer tumours and the circulating tumour cells...
2 October 2015 | By Victoria White
Genesphere's goal is to license the 3DNA platform to pharmaceutical partners and complete the preclinical work necessary to advance the its own lead drug candidates...
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
25 September 2015 | By Victoria White
The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
23 September 2015 | By Victoria White
The new smart research robot, developed at Uppsala University, accelerates research on cancer treatments by finding optimal treatment combinations...
23 September 2015 | By Victoria White
Inquiro gathers all unstructured data – from R&D to preclinical data – and allows researchers to organise and interconnect such data, facilitating large-scale collaborations among geographically distant research teams...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
